戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1 brentuximab vedotin and 65 to physician's choice), with 128 analysed in the intention-to-treat population (64 in each gro
2                                             Safety was also analysed in the intention-to treat population.
3                                             Safety was also analysed in the intention-to-treat population for our main an
4                                             Safety was also analysed in the intention-to-treat population.
5 eks post-treatment), assessed within each HCV genotype, and analysed in the intention-to-treat population.
6 utuzumab-ibrutinib versus standard chemoimmunotherapy, both analysed in the intention-to-treat population (ie, all patien
7 as the time from randomisation until death from any cause), analysed in the intention-to-treat population.
8 al response at 12 weeks (SVR12) after treatment completion, analysed in the intention-to-treat population.
9  unstable angina, and hospital admission for heart failure, analysed in the intention-to-treat population (all participan
10                                   Primary outcomes were OS (analysed in the intention-to-treat population) and adverse ev
11                                            Safety outcomes, analysed in the intention-to-treat population, included solic
12 n Test (WMFT) at the end of the 2 week intervention period, analysed in the intention-to-treat population.
13  were the safety and tolerability of the treatment regimen, analysed in the intention-to-treat population.
14 TEC-3 trial were overall survival and failure-free survival analysed in the intention-to-treat population.
15          The primary endpoint was progression-free survival analysed in the intention-to-treat population.
16                   The primary endpoint was overall survival analysed in the intention-to-treat population.
17 radiographic progression-free survival and overall survival analysed in the intention-to-treat population.
18  Criteria in Solid Tumours version 1.1 and overall survival analysed in the intention-to-treat population.
19 dpoints reported here are 5-year progression-free survival (analysed in the intention-to-treat population) and disease-fr
20 points were overall survival and progression-free survival, analysed in the intention-to-treat population (n=675), with d
21                  The primary endpoint was overall survival, analysed in the intention-to-treat population, using a two-st
22                  The primary endpoint was overall survival, analysed in the intention-to-treat population.
23 r glucose, and insulin from an oral glucose tolerance test) analysed in the intention-to-treat population.
24 ophil percentage from baseline to 12 weeks after treatment, analysed in the intention-to-treat population.
25  21 days after randomisation and, in our main analysis, was analysed in the intention-to-treat population, which comprise
26 nce-free survival, as assessed by the investigator, and was analysed in the intention-to-treat population.
27 rall survival was a prespecified secondary endpoint and was analysed in the intention-to-treat population.
28                                                Efficacy was analysed in the intention-to-treat population and safety was
29                                                Efficacy was analysed in the intention-to-treat population and safety was
30                                                Efficacy was analysed in the intention-to-treat population; safety was ana
31                                    The primary endpoint was analysed in the intention-to-treat population; safety was ana
32 of invasive and non-invasive IBTR as a first recurrence was analysed in the intention-to-treat population, excluding thos
33                                           Pain response was analysed in the intention-to-treat population with baseline a
34                                        Overall survival was analysed in the intention-to-treat population and safety was
35                                                Survival was analysed in the intention-to-treat population.
36 orced expiratory volume in 1 s (FEV1) on day 169, which was analysed in the intention-to-treat population.
37                                                   Data were analysed in the intention-to-treat population, which included
38                                          Efficacy data were analysed in the intention-to-treat population.
39                                     Efficacy endpoints were analysed in the intention-to-treat population and safety was
40                                     Efficacy endpoints were analysed in the intention-to-treat population, and safety was
41                                        These endpoints were analysed in the intention-to-treat population.
42                                     Efficacy endpoints were analysed in the intention-to-treat population.
43                                               Outcomes were analysed in the intention-to-treat population.
44                                       10-year outcomes were analysed in the intention-to-treat population.
45                                           All outcomes were analysed in the intention-to-treat population.
46                                         These outcomes were analysed in the intention-to-treat population.
47 of BPI-SF item 3, and patient-reported outcomes (PROs) were analysed in the intention-to-treat population with baseline a
48     EORTC QLQ-C30, EORTC QLQ-MY20, and FACT-GP5 scores were analysed in the intention-to-treat population, and PRO-CTCAE
49 ant difference in disease-free survival between groups when analysed in the intention-to-treat population.
50 ified primary outcome was units of blood collected per year analysed in the intention-to-treat population.